Machine learning models improve prediction of immunotherapy outcomes across multiple cancer types

Denikitug shows immune activation and early anti-tumour activity in advanced solid tumour

Zedoresertib plus lunresertib shows promising tumour shrinkage in CCNE1-amplified and FBXW7-mutant cancers

Dual integrin inhibitor plus pembrolizumab shows durable responses in ICI-resistant solid tumours

Oral molecular glue degrader with or without spartalizumab shows immune activation and tumour control in solid tumours

ctDNA positivity predicts poor response and recurrence risk in triple-negative breast cancer

Daraxonrasib plus chemotherapy shows promising first-line activity in RAS-mutant metastatic pancreatic cancer

ZL-1310 shows promising activity in DLL3-positive neuroendocrine carcinomas

DLL3 expression in circulating tumour cells predicts response to tarlatamab in small cell lung cancer

Oncolytic adenovirus VCN-01 plus chemo shows promising survival benefit in metastatic pancreatic cancer

Trastuzumab and tucatinib enable organ preservation in HER2-positive rectal cancer

Rilvegostomig clears ctDNA and delays recurrence in high-risk head and neck cancer